May 19, 2020 / 11:56 AM / 14 days ago

BRIEF-Genocea Announces Material Transfer And License Option Agreement With Shionogi For Proprietary Gen-003 Hsv-2 Antigens

May 19 (Reuters) - Genocea Biosciences Inc:

* GENOCEA ANNOUNCES MATERIAL TRANSFER AND LICENSE OPTION AGREEMENT WITH SHIONOGI FOR PROPRIETARY GEN-003 HSV-2 ANTIGENS

* GENOCEA BIOSCIENCES INC - SHIONOGI WILL PAY $2 MILLION FOR EXCLUSIVE OPTION TO EVALUATE HSV-2 ANTIGENS

* GENOCEA BIOSCIENCES INC - FINAL TERMS OF LICENSE AGREEMENT WILL BE BASED ON RESULTS OF MTA EVALUATION AND OVERALL DILIGENCE

* GENOCEA BIOSCIENCES - IF LICENSED, SHIONOGI WILL ASSUME RESPONSIBILITY FOR GLOBAL DEVELOPMENT AND COMMERCIALIZATION OF HSV-2 VACCINE PRODUCT Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below